Great Lakes Advisors’s Acadia Pharmaceuticals ACAD Stock Holding History

Great Lakes Advisors’s Portfolio ACAD Stock Details ACAD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$3.83M	Sell	151,341 -90,486	-37%	-$1.99M	0.03%	293
2026 Q1	$5.38M	Sell	241,827 -71,709	-23%	-$1.71M	0.04%	211
2025 Q4	$8.37M	Sell	313,536 -141,254	-31%	-$3.38M	0.07%	171
2025 Q3	$9.71M	Sell	454,790 -333,245	-42%	-$7.88M	0.08%	168
2025 Q2	$17M	Buy	788,035 +175,355	+29%	+$3.26M	0.14%	137
2025 Q1	$10.2M	Buy	612,680 +72,667	+13%	+$1.32M	0.09%	192
2024 Q4	$9.91M	Buy	+540,013	New	+$8.72M	0.08%	203
2021 Q2	–	Sell	-482,666	Closed	-$12.5M	–	703
2021 Q1	$12.5M	Buy	482,666 +32,152	+7%	+$1.42M	0.2%	157
2020 Q4	$24.1M	Buy	+450,514	New	+$22.4M	0.44%	66
2018 Q4	–	Sell	-202,452	Closed	-$4.2M	–	558
2018 Q3	$4.2M	Sell	202,452 -11,521	-5%	-$181K	0.09%	219
2018 Q2	$3.27M	Buy	+213,973	New	+$3.82M	0.08%	252

Other funds holding ACAD

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Great Lakes Advisors's ACAD Position: Q2 2026 in Review

Great Lakes Advisors reduced its Acadia Pharmaceuticals (ACAD) stake by 37% in Q2 2026, selling an estimated $1.99M and leaving 151,341 shares worth $3.83M. The position accounts for 0.03% of the portfolio, ranked #293.

Great Lakes Advisors first reported a position in ACAD in Q2 2018 and has held it in 11 quarters since. The position peaked at $24.1M in Q4 2020. 354 funds tracked by Wall St. Rank hold ACAD as of Q2 2026.

Great Lakes Advisors held 151,341 shares of Acadia Pharmaceuticals worth $3.83M as of Q2 2026.
Great Lakes Advisors sold 90,486 Acadia Pharmaceuticals shares in Q2 2026, an estimated $1.99M.
Acadia Pharmaceuticals made up 0.03% of Great Lakes Advisors's portfolio in Q2 2026, its #293 holding.
Great Lakes Advisors first reported a position in Acadia Pharmaceuticals in Q2 2018 and has held it in 11 quarters since.
Great Lakes Advisors's Acadia Pharmaceuticals position peaked at $24.1M in Q4 2020.
354 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q2 2026.

Based on Great Lakes Advisors's 13F filing for Q2 2026, filed 10 Aug 2026.